Recently Expired Drugs
1. Abraxane patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7820788 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Apr, 2025
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-658) | Oct 11, 2015 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| M(M-14) | Dec 06, 2022 |
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: NA
Dosage: POWDER
How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage
ABRAXANE family patents
2. Admelog Solostar patent expiration
ADMELOG SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI-AVENTIS US | Pen-type injector |
Apr, 2025
(23 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2020 |
Drugs and Companies using INSULIN LISPRO ingredient
Market Authorisation Date: 11 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ADMELOG SOLOSTAR family patents
3. Aemcolo patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263120 | COSMO TECHNOLOGIES | Oral antimicrobial pharmaceutical compositions |
May, 2025
(2 days ago) | |
| US8741948 | COSMO TECHNOLOGIES | Oral antimicrobial pharmaceutical compositions |
May, 2025
(2 days ago) | |
| US8486446 | COSMO TECHNOLOGIES | Oral antimicrobial pharmaceutical compositions |
May, 2025
(2 days ago) | |
| US8529945 | COSMO TECHNOLOGIES | Oral antimicrobial pharmaceutical compositions |
May, 2025
(2 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 16, 2028 |
Drugs and Companies using RIFAMYCIN SODIUM ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2018
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
AEMCOLO family patents
4. Ampyra patent expiration
AMPYRA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440703 | MERZ | Methods of using sustained release aminopyridine compositions |
Apr, 2025
(27 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
Drugs and Companies using DALFAMPRIDINE ingredient
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage
AMPYRA family patents
5. Anoro Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(8 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.
Dosage: POWDER
More Information on Dosage
ANORO ELLIPTA family patents
6. Antara (micronized) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8026281 | LUPIN | Treating metabolic syndrome with fenofibrate |
Apr, 2025
(13 days ago) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 30 November, 2004
Treatment: Treating primary hypercholesterolemia and mixed dyslipidemia
Dosage: CAPSULE
How can I launch a generic of ANTARA (MICRONIZED) before it's drug patent expiration?
More Information on Dosage
ANTARA (MICRONIZED) family patents
7. Apidra Solostar patent expiration
APIDRA SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI AVENTIS US | Pen-type injector |
Apr, 2025
(23 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
APIDRA SOLOSTAR family patents
8. Auvi-q patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(5 days ago) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
AUVI-Q family patents
9. Brilinta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE46276 (Pediatric) | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Apr, 2025
(5 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
| New Indication(I-714) | Sep 03, 2018 |
| New Strength(NS) | Sep 03, 2018 |
| New Indication(I-851) | May 28, 2023 |
| New Indication(I-848) | Nov 05, 2023 |
| M(M-283) | May 09, 2025 |
| Pediatric Exclusivity(PED) | Nov 09, 2025 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage
BRILINTA family patents
10. Brisdelle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598271 | LEGACY PHARMA | Crystalline paroxetine methane sulfonate |
May, 2025
(a day ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2016 |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 28 June, 2013
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of BRISDELLE before it's drug patent expiration?
More Information on Dosage
BRISDELLE family patents
11. Bydureon patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2015 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adju...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON family patents
12. Bydureon Bcise patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2020 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON BCISE family patents
13. Bydureon Pen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet ...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON PEN family patents
14. Cabenuva Kit patent expiration
CABENUVA KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(14 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-184) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
CABENUVA KIT family patents
15. Complera patent expiration
COMPLERA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(14 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| New Patient Population(NPP) | Dec 13, 2016 |
NCE-1 date: 21 May, 2015
Market Authorisation Date: 10 August, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage
COMPLERA family patents
16. Edurant patent expiration
EDURANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(14 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| New Patient Population(NPP) | Aug 26, 2018 |
| M(M-223) | Feb 01, 2021 |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 21 May, 2015
Market Authorisation Date: 20 May, 2011
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy
Dosage: TABLET
More Information on Dosage
EDURANT family patents
17. Edurant Ped patent expiration
EDURANT PED's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(14 days ago) | |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 March, 2024
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral treatment-naive patients 2 years of age and older, weighing at least 14kg, with hiv-1 rna less th...
Dosage: TABLET, FOR SUSPENSION
More Information on Dosage
EDURANT PED family patents
18. Evzio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(5 days ago) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO family patents
19. Evzio (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(5 days ago) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO (AUTOINJECTOR) family patents
20. Farxiga patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(22 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
21. Fotivda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2025
(9 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2025
Market Authorisation Date: 10 March, 2021
Treatment: A method of treating adults with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies by inhibiting the angiogenesis of blood vessels with a vascular end...
Dosage: CAPSULE
More Information on Dosage
FOTIVDA family patents
22. Glyxambi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(3 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage
GLYXAMBI family patents
23. Horizant patent expiration
HORIZANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(29 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-652) | Jun 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
| Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage
HORIZANT family patents
24. Incruse Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7498440 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(8 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309572 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-172) | Feb 24, 2019 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 30 April, 2014
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.
Dosage: POWDER
More Information on Dosage
INCRUSE ELLIPTA family patents
25. Inlyta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6534524 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Apr, 2025
(6 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage
INLYTA family patents
26. Invokamet patent expiration
INVOKAMET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(24 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 08 August, 2014
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET
How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage
INVOKAMET family patents
27. Invokamet Xr patent expiration
INVOKAMET XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(24 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Indication(I-788) | Oct 29, 2021 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 20 September, 2016
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage
INVOKAMET XR family patents
28. Invokana patent expiration
INVOKANA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(24 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Indication(I-809) | Sep 27, 2022 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 29 March, 2013
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET
How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage
INVOKANA family patents
29. Jentadueto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(3 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-146) | Jul 30, 2017 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage
JENTADUETO family patents
30. Jentadueto Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(3 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage
JENTADUETO XR family patents
31. Juluca patent expiration
JULUCA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(14 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage
JULUCA family patents
32. Kyprolis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8207297 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(21 days ago) | |
| US8207125 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(21 days ago) | |
| US7232818 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(21 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7491704 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(21 days ago) | |
| US8207126 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(21 days ago) | |
| US8207127 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(21 days ago) | |
| US8129346 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(21 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-722) | Jan 21, 2019 |
| New Indication(I-723) | Jan 21, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| New Indication(I-842) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 20 July, 2016
Market Authorisation Date: 07 June, 2018
Treatment: Kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; Kyprolis is indicated in combination ...
Dosage: POWDER
How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage
KYPROLIS family patents
33. Lantus Solostar patent expiration
LANTUS SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI AVENTIS US | Pen-type injector |
Apr, 2025
(23 days ago) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LANTUS SOLOSTAR family patents
34. Naloxone Hydrochloride (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(5 days ago) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents
35. Odefsey patent expiration
ODEFSEY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(14 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-206) | Aug 21, 2020 |
| M(M-207) | Aug 21, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 01 March, 2016
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage
ODEFSEY family patents
36. Onivyde patent expiration
ONIVYDE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8992970 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(3 days ago) | |
| US9724303 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(3 days ago) | |
| US10722508 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(3 days ago) | |
| US9782349 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(3 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9730891 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(3 days ago) | |
| US8703181 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(3 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 22, 2022 |
| Orphan Drug Exclusivity(ODE-99) | Oct 22, 2022 |
| New Indication(I-932) | Feb 13, 2027 |
| Orphan Drug Exclusivity(ODE-463) | Feb 13, 2031 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer
Dosage: INJECTABLE, LIPOSOMAL
More Information on Dosage
ONIVYDE family patents
37. Oraverse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7575757 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Apr, 2025
(14 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 18, 2019 |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Market Authorisation Date: 09 May, 2008
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
ORAVERSE family patents
38. Oxycontin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776314 | PURDUE PHARMA LP | Abuse-proofed dosage system |
Apr, 2025
(16 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2010
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OXYCONTIN family patents
39. Pexeva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(a day ago) | |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 03 July, 2003
Treatment: NA
Dosage: TABLET
More Information on Dosage
PEXEVA family patents
40. Soliqua 100/33 patent expiration
SOLIQUA 100/33 IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI-AVENTIS US | Pen-type injector |
Apr, 2025
(23 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SOLIQUA 100/33 family patents
41. Stendra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6656935 | METUCHEN PHARMS | Aromatic nitrogen-containing 6-membered cyclic compounds |
Apr, 2025
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 27, 2017 |
| New Dosing Schedule(D-140) | Sep 17, 2017 |
| M(M-282) | Oct 18, 2025 |
Drugs and Companies using AVANAFIL ingredient
NCE-1 date: 27 April, 2016
Market Authorisation Date: 27 April, 2012
Treatment: Treatment of erectile dysfunction
Dosage: TABLET
How can I launch a generic of STENDRA before it's drug patent expiration?
More Information on Dosage
STENDRA family patents
42. Symtuza patent expiration
SYMTUZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7390791 | JANSSEN PRODS | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(18 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage
SYMTUZA family patents
43. Toujeo Max Solostar patent expiration
TOUJEO MAX SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI US SERVICES | Pen-type injector |
Apr, 2025
(23 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TOUJEO MAX SOLOSTAR family patents
44. Toujeo Solostar patent expiration
TOUJEO SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI US SERVICES | Pen-type injector |
Apr, 2025
(23 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TOUJEO SOLOSTAR family patents
45. Tradjenta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(3 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-118) | Aug 13, 2015 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage
TRADJENTA family patents
46. Trelegy Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(8 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| New Indication(I-775) | Apr 24, 2021 |
| New Indication(I-843) | Sep 09, 2023 |
| New Strength(NS) | Sep 09, 2023 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 September, 2017
Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via top...
Dosage: POWDER
More Information on Dosage
TRELEGY ELLIPTA family patents
47. Tri-luma patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7939516 | GALDERMA LABS LP | Topical skin care composition |
May, 2025
(a day ago) | |
Drugs and Companies using FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN ingredient
Market Authorisation Date: 18 January, 2002
Treatment: NA
Dosage: CREAM
More Information on Dosage
TRI-LUMA family patents
48. Trijardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(3 days ago) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage
TRIJARDY XR family patents
49. Vizimpro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623883 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
May, 2025
(15 hours ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2023 |
| Orphan Drug Exclusivity(ODE-206) | Sep 27, 2025 |
| Orphan Drug Exclusivity(ODE-213) | Sep 27, 2025 |
Drugs and Companies using DACOMITINIB ingredient
NCE-1 date: 27 September, 2022
Market Authorisation Date: 27 September, 2018
Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test
Dosage: TABLET
More Information on Dosage
VIZIMPRO family patents
50. Vyxeos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431806 | CELATOR PHARMS | Liposomal formulations of anthracycline agents and cytidine analogs |
Apr, 2025
(13 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 03, 2020 |
| New Patient Population(NPP) | Mar 30, 2024 |
| Orphan Drug Exclusivity(ODE-287) | Aug 03, 2024 |
| Orphan Drug Exclusivity(ODE-350) | Mar 30, 2028 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older
Dosage: POWDER
More Information on Dosage
VYXEOS family patents